https://www.shasqi.com https://www.shasqi.com/about https://www.shasqi.com/access-denied https://www.shasqi.com/careers https://www.shasqi.com/contact https://www.shasqi.com/leadership https://www.shasqi.com/log-in https://www.shasqi.com/news https://www.shasqi.com/news-page https://www.shasqi.com/our-platform https://www.shasqi.com/our-science-copy https://www.shasqi.com/pipeline https://www.shasqi.com/reset-password https://www.shasqi.com/sign-up https://www.shasqi.com/styleguide https://www.shasqi.com/update-password https://www.shasqi.com/user-account https://www.shasqi.com/post/2023-aacr-novel-protodrugs-capac-a-modular-platform-that-can-improve-the-safety-and-efficacy-of-existing-cancer-therapies https://www.shasqi.com/post/a-hyaluronate-derivative-biopolymer-enables-activation-of-protodrugs-at-tumors-in-animals-and-humans-using-click-chemistry https://www.shasqi.com/post/at-jpm-shasqi-highlights-how-click-chemistry-can-tackles-adcs-1-problem https://www.shasqi.com/post/attenuated-mmae-therapeutic-activated-by-click-chemistry-at-the-tumor-evokes-potent-immune-responses https://www.shasqi.com/post/bioworld-highlights-shasqis-poster-presentations-at-esmo-2022 https://www.shasqi.com/post/ceacam5-is-an-ideal-target-for-click-chemistry-enabled-pre-targeting https://www.shasqi.com/post/ceacam5-is-an-ideal-target-for-click-chemistry-enabled-pre-targeting-2 https://www.shasqi.com/post/ceacam5-pre-targeting-via-click-chemistry-enables-tumor-selective-mmae-activation-a-first-in-class-approach-to-enhance-clinical-benefit-in-targeted-therapy https://www.shasqi.com/post/cen-click-and-bioorthogonal-chemistry-win-2022-nobel-prize-in-chemistry https://www.shasqi.com/post/cen-click-chemistry-sees-first-use-in-humans https://www.shasqi.com/post/chemistry-world-the-bioorthogonal-revolution https://www.shasqi.com/post/click-activated-protodrugs-against-cancer-increase-the-therapeutic-potential-of-chemotherapy-through-local-capture-and-activation https://www.shasqi.com/post/click-chemistry-breakthroughs-drive-shasqi-and-j-j-cancer-alliance https://www.shasqi.com/post/click-chemistry-selectively-activates-an-auristatin-protodrug-with-either-intratumoral-or-systemic-tumor-targeting-agents https://www.shasqi.com/post/derek-lowe-click-chemotherapy https://www.shasqi.com/post/development-of-a-first-in-class-click-chemistry-based-cancer-therapeutic-from-preclinical-evaluation-to-a-first-in-human-dose-escalation-clinical-trial https://www.shasqi.com/post/discover-magazine-honeymoon-phase-chemical-partners-deliver-a-toxic-drug-to-tumors https://www.shasqi.com/post/drug-discovery-development-click-chemistry-company-shasqi-has-a-link-to-the-nobel-prize-in-chemistry https://www.shasqi.com/post/drug-discovery-world-the-nobel-prize-winning-power-of-click-chemistry https://www.shasqi.com/post/endpoints-news-investors-bet-on-small-biotechs-mission https://www.shasqi.com/post/endpoints-pioneering-click-chemistry-in-humans https://www.shasqi.com/post/fierce-biotech-shasqi-snatches-50m-series-b https://www.shasqi.com/post/forbes-side-effects-from-chemo-can-be-devastating-this-startup-aims-to-change-that https://www.shasqi.com/post/healio-nobel-laureate-takes-pride-in-success-of-bioorthogonal-chemistry-for-cancer-treatment https://www.shasqi.com/post/how-a-small-biotech-worked-its-way-out-of-storage-space-during-the-industrys-biggest-conference https://www.shasqi.com/post/implantable-biomaterial-based-on-click-chemistry-for-targeting-small-molecules https://www.shasqi.com/post/in-vivo-bioorthogonal-chemistry-enables-local-hydrogel-and-systemic-pro-drug-to-treat-soft-tissue-sarcoma https://www.shasqi.com/post/life-science-leader-translating-nobel-prize-winning-science-into-medicine https://www.shasqi.com/post/macalester-alumni-magazine-partners-with-a-purpose https://www.shasqi.com/post/mmae-payload-separated-from-her2-targeting-agent-is-selectively-activated-at-tumors-through-click-chemistry-in-vivo https://www.shasqi.com/post/mmae-payload-uncoupled-from-her2-targeting-agent-is-selectively-activated-at-tumors-through-click-chemistry-in-vivo https://www.shasqi.com/post/nature-biotech-clicked-drugs-researchers-prove-the-remarkable-chemistry-in-humans https://www.shasqi.com/post/nature-click-chemistry-targets-antibody-drug-conjugates-for-the-clinic https://www.shasqi.com/post/nectin-4-targeted-therapy-with-mmae-protodrug-results-in-anti-tumor-efficacy-mediated-by-click-chemistry https://www.shasqi.com/post/nobel-connected-startup-shasqi-deepens-j-j-partnership-on-capac-platform https://www.shasqi.com/post/pharmas-almanac-what-do-you-view-as-the-most-disruptive-or-transformational-technology-or-development-on-the-horizon https://www.shasqi.com/post/pharmavoice-the-first-company-to-use-nobel-winning-click-chemistry-in-humans-is-on-a-mission-to-transform-oncology https://www.shasqi.com/post/phase-1-clinical-results-of-sq3370-a-doxorubicin-based-click-chemistry-therapeutic-in-advanced-solid-tumor-patients https://www.shasqi.com/post/phase-2a-results-of-sq3370-a-doxorubicin-based-click-chemistry-therapeutic-in-advanced-sts-patients-planned-interim-analysis https://www.shasqi.com/post/pre-targeting-with-in-vivo-click-chemistry-enables-preferential-drug-exposure-in-tumors-versus-normal-tissues https://www.shasqi.com/post/pre-targeting-with-in-vivo-click-chemistry-enables-preferential-drug-exposure-in-tumors-versus-normal-tissues-3 https://www.shasqi.com/post/san-francisco-business-times-peninsula-biotech-looks-to-click-fresh-50m-into-new-approach-against-cancer https://www.shasqi.com/post/san-francisco-business-times-the-long-game-nobel-prize-winners-pay-it-forward https://www.shasqi.com/post/sf-business-times-click-chemistry-company-shasqi-just-struck-a-deal-with-johnson-johnson https://www.shasqi.com/post/shasqi-advances-sq3370-to-phase-2-in-solid-tumors https://www.shasqi.com/post/shasqi-announces-click-chemistry-breakthrough-with-first-ever-human-application-in-launch-of-clinical-program https://www.shasqi.com/post/shasqi-announces-publication-of-preclinical-data-demonstrating-proof-of-principle-for-click-activated-approach-to-cancer-treatment https://www.shasqi.com/post/shasqi-announces-research-collaboration-to-transform-targeted-cancer-treatment https://www.shasqi.com/post/shasqi-announces-strategic-advisors-as-it-advances-click-chemistry-based-treatments-for-cancer https://www.shasqi.com/post/shasqi-announces-two-abstracts-accepted-for-poster-presentation-at-the-sitc-39th-annual-meeting-held-november-8-10-2024-in-houston-tx https://www.shasqi.com/post/shasqi-appoints-oncology-luminaries-to-its-inaugural-scientific-advisory-board-alongside-the-expansion-of-its-leadership-team https://www.shasqi.com/post/shasqi-appoints-travis-biechele-ph-d-as-vp-of-research-to-lead-pipeline-development https://www.shasqi.com/post/shasqi-awarded-prestigious-direct-to-phase-2-small-business-innovation-research-grant-by-national-cancer-institute https://www.shasqi.com/post/shasqi-ceo-jose-mejia-oneto-speaking-on-panel-at-lsxusa-world-congress-on-september-11th https://www.shasqi.com/post/shasqi-completes-10-million-series-a-financing https://www.shasqi.com/post/shasqi-demonstrates-chemistry-based-platform-produces-local-and-systemic-anti-tumor-response-in-preclinical-cancer-model https://www.shasqi.com/post/shasqi-design1-76e341769f4c85549f586a53-webflow-io-post-sq3370-activates-cytotoxic-drug-via-click-chemistry-at-tumor-and-elicits-sustained-responses-in-injected-and-non-injected-lesions https://www.shasqi.com/post/shasqi-expands-board-of-directors-with-appointment-of-biopharma-executives https://www.shasqi.com/post/shasqi-presenting-two-sessions-at-world-adc-2024 https://www.shasqi.com/post/shasqi-presents-initial-data-validating-approach-of-click-chemistry-activated-oncology-therapeutics-at-esmo-congress-2022 https://www.shasqi.com/post/shasqi-presents-preclinical-and-trial-in-progress-posters-at-ctos-2021 https://www.shasqi.com/post/shasqi-presents-trial-in-progress-and-preclinical-posters-at-sitc-2021 https://www.shasqi.com/post/shasqi-publishes-data-on-systemic-antigen-targeting-approach-using-click-chemistry-to-activate-mmae-in-tumors https://www.shasqi.com/post/shasqi-publishes-landmark-study-in-clinical-cancer-research-first-in-human-use-of-click-chemistry-unlocks-new-opportunities-for-targeted-cancer-therapies https://www.shasqi.com/post/shasqi-raises-50-million-to-expand-click-chemistry-platform-beyond-injectable-tumors-and-accelerate-lead-clinical-program https://www.shasqi.com/post/shasqi-scientific-advisor-carolyn-bertozzi-awarded-nobel-prize-for-the-development-of-click-chemistry https://www.shasqi.com/post/shasqi-speaking-at-adc-radiopharmaceuticals-pharma-biotech-partner-summit https://www.shasqi.com/post/shasqi-strengthens-board-of-directors-with-the-appointment-of-former-chief-development-officer-at-pfizer-oncology https://www.shasqi.com/post/shasqi-to-expand-existing-research-collaboration-to-advance-targeted-cancer-treatment https://www.shasqi.com/post/shasqi-to-present-at-39th-annual-jp-morgan-healthcare-conference-on-wednesday-january-13-2022 https://www.shasqi.com/post/shasqi-to-present-at-43rd-annual-j-p-morgan-healthcare-conference https://www.shasqi.com/post/shasqi-to-present-at-the-40th-annual-jp-morgan-healthcare-conference-2022 https://www.shasqi.com/post/shasqi-to-present-at-world-adc-and-sitc-conferences https://www.shasqi.com/post/shasqi-to-present-data-on-novel-click-chemistry-platform-at-the-american-association-for-cancer-research-aacr-annual-meeting https://www.shasqi.com/post/shasqi-to-present-data-on-novel-tumor-targeted-drug-activation-technology-at-2024-american-association-for-cancer-research-aacr-annual-meeting https://www.shasqi.com/post/shasqi-to-present-data-updates-at-upcoming-sitc-and-ctos-meetings https://www.shasqi.com/post/shasqi-to-present-new-data-at-2024-world-adc-london-conference https://www.shasqi.com/post/shasqi-to-present-on-sq3370-and-capac-platform-expansion-at-the-american-association-for-cancer-research-aacr-2022-annual-meeting https://www.shasqi.com/post/shasqi-to-present-updated-clinical-data-on-sq3370-at-the-2022-asco-annual-meeting https://www.shasqi.com/post/shasqis-local-drug-activation-technology-provides-improved-drug-efficacy-with-minimal-side-effects https://www.shasqi.com/post/sq3370-the-first-clinical-click-chemistry-activated-cancer-therapeutic-shows-safety-in-humans-and-translatability-across-species https://www.shasqi.com/post/stanford-magazine-carolyn-bertozzi-talks-bioorthogonal-chemistry-in-life-is-sweet https://www.shasqi.com/post/stat-news-it-takes-two-the-future-of-click-chemistry-therapeutics https://www.shasqi.com/post/the-bio-report-a-company-that-bets-its-therapies-will-click-with-patients https://www.shasqi.com/post/tumor-selective-mmae-activation-via-ceacam5-pre-targeting-using-click-chemistry-a-first-in-class-strategy-to-enhance-clinical-benefit https://www.shasqi.com/post/tumor-selective-mmae-activation-via-ceacam5-pre-targeting-using-click-chemistry-a-first-in-class-strategy-to-enhance-clinical-benefit-2 https://www.shasqi.com/post/washington-post-nobel-prize-awarded-to-three-scientists-for-work-in-click-chemistry-which-links-molecules-quickly